ANTI-DR5 ANTIBODIES AND METHODS OF USE THEREOF

    公开(公告)号:US20210324096A1

    公开(公告)日:2021-10-21

    申请号:US17108373

    申请日:2020-12-01

    Applicant: GENMAB B.V.

    Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

    ANTI-DR5 ANTIBODIES AND METHODS OF USE THEREOF

    公开(公告)号:US20190315877A1

    公开(公告)日:2019-10-17

    申请号:US16451714

    申请日:2019-06-25

    Applicant: GENMAB B.V.

    Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signaling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

    ANTIBODY VARIANT COMBINATIONS AND USES THEREOF

    公开(公告)号:US20220411529A1

    公开(公告)日:2022-12-29

    申请号:US17774333

    申请日:2020-11-06

    Applicant: GENMAB B.V.

    Abstract: The invention relates to combination therapy involving two or more antibodies, wherein the Fc regions of the two antibodies have been modified such that hetero-oligomerization between the antibodies is strongly favored over self-oligomerization when antibodies are bound to their corresponding target antigens and such that hetero-oligomerization-independent effector functions of one or both antibodies are eliminated or strongly reduced. The invention also relates to antibodies, compositions, and kits suitable for use in the combination therapy of the invention.

Patent Agency Ranking